Skip to main content

Table 1 Outcomes extracted from the randomized clinical trials and included into the mixed treatment comparison

From: Systematic review and mixed treatment comparison meta-analysis of randomized clinical trials of primary oral antifungal prophylaxis in allogeneic hematopoietic cell transplant recipients

Study

All-cause mortality

Incidence of proven/probable IFI overall

Incidence of proven/probable IA

Incidence of proven IC

Incidence of OLAT use

Winston 2003 [29]

     

Fluconazole

28/67 (42%)

17/67 (25%)

8/67 (12%)

8/67 (12%)

Not reported

Itraconazole

32/71 (45%)

6/71 (8%)

3/71 (4%)

2/71 (3%)

Not reported

Marr 2004 [26]

     

Fluconazole

44/148 (30%)

25/148 (17%)

20/148 (14%)

5/148 (3%)

25/148 (17%)

Itraconazole

55/151 (36%)

19/151 (13%)a

16/151 (11%)

4/151 (3%)

19/151 (13%)

Ullmann 2007 [27]

     

Fluconazole

59/299 (20%)

27/299 (9%)

21/299 (7%)

4/299 (1%)

29/288 (10%)

Posaconazole

58/301 (19%)

16/301 (5%)

7/301 (2%)

4/301 (1%)

31/291 (11%)

Wingard 2010 [28]

     

Fluconazole

59/295 (20%)

24/295 (8%)

17/295 (6%)

5/295 (2%)

89/295 (30%)

Voriconazole

57/305 (19%)

14/305 (5%)

9/305 (3%)

3/305 (1%)

73/305 (24%)

Marks 2011 [10]

     

Itraconazole

44/241 (18%)

5/241 (2%)

5/241(2%)

0/241 (0%)

101/241 (42%)

Voriconazole

40/224 (18%)

3/224 (1%)

1/224 (0.4%)

2/224 (1%)

67/224 (30%)

  1. IFI, invasive fungal infections; IA, invasive aspergillosis; IC, invasive candidiasis; OLAT, other licensed antifungal therapy.
  2. aOne patient developed both proven IC and probable IA, which was counted as a single IFI instead of 2 separate IFIs.